Meeting
2012 ASCO Annual Meeting
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
Authors
Marc Ryan Matrana
University of Texas M. D. Anderson Cancer Center, Houston, TX
Marc Ryan Matrana , Aditya V. Shetty , Bradley J. Atkinson , Lianchun Xiao , Paul G. Corn , Randall E. Millikan , Eric Jonasch , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4615)
DOI
10.1200/jco.2012.30.15_suppl.4615
Abstract #
4615
Poster Bd #
6F
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2012 Genitourinary Cancers Symposium
Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series.
First Author: Amber Flaherty
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu